Evaluating IL-21 as a Potential Therapeutic Target in Crohn's Disease.

ABSTRACT:

Background and aim

Interleukin-21 (IL-21) is primarily a T cell-derived cytokine; it is upregulated in patients with Crohn's Disease (CD) and could be a potential new therapeutic target in CD.

Methods

In human material, IL-21 and IL-21R expression was investigated by in situ hybridization (ISH) and immunohistochemistry (IHC) in noninflammatory bowel disease (non-IBD) controls and patients with CD. The pathologic role of IL-21 was examined in murine models of T cell-dependent and T cell-independent colitis, either with a neutralizing monoclonal antibody against IL-21 or with the transfer of CD4⁺CD45RB^highIL-21R^-/- T cells. Colonic pathology was examined by endoscopy, histopathology, IHC, ELISA, and Luminex.

Results

In the human intestin

SUBMITTER: Holm TL 

PROVIDER: S-EPMC5914125 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature